MIM
MRNS

Macroview Investment Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Macroview Investment Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-351
Closed -$618 – 586
2024
Q3 		$618 Hold
351
– – ﹤0.01% 531
2024
Q2 		$411 Hold
351
– – ﹤0.01% 545
2024
Q1 		$3.17K Sell
351
-679
-66% -$6.6K ﹤0.01% 466
2023
Q4 		$11.2K Sell
1,030
-257
-20% -$1.93K 0.01% 239
2023
Q3 		$10.4K Buy
+1,287
New +$10.7K 0.01% 253

Other funds holding MRNS

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Macroview Investment Management's MRNS Position: Q4 2024 in Review

Macroview Investment Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2024, closing a stake of 351 shares — an estimated $618 sold.

Macroview Investment Management first reported a position in MRNS in Q3 2023 and held it in 5 quarters. The position peaked at $11.2K in Q4 2023. 53 funds tracked by Wall St. Rank hold MRNS as of Q4 2024.

  • Macroview Investment Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2024 after selling out during the quarter.
  • Macroview Investment Management sold 351 Marinus Pharmaceuticals, Inc shares in Q4 2024, an estimated $618.
  • Macroview Investment Management first reported a position in Marinus Pharmaceuticals, Inc in Q3 2023 and held it in 5 quarters.
  • Macroview Investment Management's Marinus Pharmaceuticals, Inc position peaked at $11.2K in Q4 2023.
  • 53 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2024.

Based on Macroview Investment Management's 13F filing for Q4 2024, filed 31 Jan 2025.